Liver biochemistry abnormalities in a quaternary care lipid clinic database

The metabolic syndrome and non-alcoholic fatty liver disease are increasing at alarming rates. To determine the effect of HMG-CoA reductase inhibitors (statins) on elevated liver enzymes in patients with hyperlipidemia. Patients with AST above 60 U/L prior to or during treatment with statin therapy...

Full description

Saved in:
Bibliographic Details
Published in:Annals of hepatology 2008-01, Vol.7 (1), p.63-66
Main Authors: Wiesinger, Holly A R, Shah, J, White, A, Yoshida, E M, Frohlich, J, Sirrs, S, Gill, S, Byrne, M F
Format: Article
Language:English
Subjects:
Adult
Aspartate Aminotransferases - blood
Databases, Factual
Fatty Liver - drug therapy
Fatty Liver - metabolism
Female
HMG-CoA reductase inhibitor
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors - therapeutic use
hyperlipidemia
Hyperlipidemias - drug therapy
Hyperlipidemias - metabolism
Liver - metabolism
Male
Metabolic Syndrome - drug therapy
Metabolic Syndrome - metabolism
Middle Aged
Non-alcoholic fatty liver disease
Outpatient Clinics, Hospital
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The metabolic syndrome and non-alcoholic fatty liver disease are increasing at alarming rates. To determine the effect of HMG-CoA reductase inhibitors (statins) on elevated liver enzymes in patients with hyperlipidemia. Patients with AST above 60 U/L prior to or during treatment with statin therapy at a quaternary care lipid clinic were reviewed. A retrospective analysis was conducted. Patients were separated into two groups: Group 1--elevated AST prior to statin therapy; and Group 2--elevated AST during statin therapy. Forty six patients with one or more measurements of AST >60 U/L remained after exclusion criteria were applied. Ten of 13 (77%) group 1 patients had reduced AST levels after initiation of statin therapy. Thirty two of 33 patients (97%) in group 2 had transient AST elevations while on statin therapy; one patient had persistently elevated AST after initiation of treatment. There were no significant adverse events reported. Use of HMG-CoA reductase inhibitors in patients with elevated AST resulted in normalization of AST levels. HMG-CoA reductase inhibitors were safe in patients with mildly elevated AST. This may translate to use of HMG-CoA reductase inhibitors in diseases such as non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
ISSN:1665-2681
DOI:10.1016/S1665-2681(19)31889-7